A Placebo-Controlled Effectiveness in INPH Shunting (PENS) Trial
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Mark Luciano, MD
Johns Hopkins University
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University of Calgary
Calgary, Alberta, Canada
- Vancouver General Hospital/university of British Colombia
Vancouver, British Colombia, Canada
- Umeå University
Umeå, Sweden
- Johns Hopkins Medicine
Baltimore, Maryland, United States
- University of New Mexico
Albuquerque, New Mexico, United States
- Cleveland Clinic
Cleveland, Ohio, United States
- University of Washington Medical Center
Seattle, Washington, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study. It may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 21 May 2018
- Primary completion
- 19 Mar 2021
- Completion
- 18 May 2021
- Last update posted
- 2 Aug 2022
- Registered enrollment
- 18
- Registry id
- NCT03350750
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.